Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir
Yakugaku Zasshi. 2022;142(10):1125-1127. doi: 10.1248/yakushi.22-00099.ABSTRACTA 55-year-old man with hypertrophic cardiomyopathy and a pacemaker was admitted with coronavirus disease 2019 (COVID-19). Before admission, the patient's medications included amiodarone, diltiazem, bisoprolol, atorvastatin, etizolam, and warfarin (WF). After admission, dexamethasone (DXM) and remdesivir (RDV) were initiated for treating COVID-19. The international normalized ratio (INR) on admission was 1.8, which increased to 3.4 on day 5 and to 6.9 on day 10 after admission. Although there have been reports that RDV may occasionally prolong pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - October 2, 2022 Category: Drugs & Pharmacology Authors: Hidetoshi Ishii Norio Yokota Yuki Bando Katsuya Otori Source Type: research
Acute interstitial nephritis related to SGLT-2 inhibitor
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors are effective antihyperglycemic agents with proven cardiovascular and renal benefits.1 2 The risk for acute kidney injury (AKI) in patients on SGLT-2 inhibitors is considered to be relatively low. However, there have been postmarketing reports of episodes of AKI, some requiring hospitalisation and even dialysis in patients receiving SGLT-2 inhibitors.3 This phenomenon may be related to volume contraction and haemodynamic changes, particularly in patients with other risk factors (such as patients on renin–angiotensin–aldosterone system blocking agents or n...
Source: Postgraduate Medical Journal - September 22, 2022 Category: General Medicine Authors: Bnaya, A., Itzkowitz, E., Atrash, J., Abu-Alfeilat, M., Shavit, L. Tags: Adverse drug reactions Source Type: research
The Efficacy and Safety of Bisoprolol in the Treatment of Myocardial Infarction with Cardiac Insufficiency
CONCLUSION: Bisoprolol combined with conventional treatment can reduce serum Hcy and CRP levels in patients with myocardial infarction and cardiac insufficiency and improve cardiac function. Moreover, there are no obvious adverse reactions during the treatment.PMID:36060658 | PMC:PMC9436541 | DOI:10.1155/2022/3098726 (Source: Computational and Mathematical Methods in Medicine)
Source: Computational and Mathematical Methods in Medicine - September 5, 2022 Category: Statistics Authors: Yan Wang Source Type: research
Effect of Enalapril Combined with Bisoprolol on Cardiac Function and Inflammatory Indexes in Patients with Acute Myocardial Infarction
CONCLUSION: Enalapril application combined with bisoprolol in AMI patients is beneficial to boost the efficacy, promote the improvement of cardiac function, reduce the inflammatory response, and improve the oxidative stress with fewer adverse effects, which can ensure the therapeutic security.PMID:36034944 | PMC:PMC9410778 | DOI:10.1155/2022/6062450 (Source: Evidence-based Complementary and Alternative Medicine)
Source: Evidence-based Complementary and Alternative Medicine - August 29, 2022 Category: Complementary Medicine Authors: Kaiyue Huang Yubin Zhang Fulin Yang Xue Luo Weiying Long Xingzhi Hou Source Type: research
Case Report: Good cardiac tolerance to Toripalimab in a CVD patient with oral melanoma
Conclusions: This case provided evidence of Toripalimab combined with chemotherapy on melanoma patients with complex cardiovascular diseases. Toripalimab demonstrated a manageable safety profile and durable clinical response. In addition, the standard CHF treatment plays a vital role in the protection of cardiac function. In a cancer patient with complex cardiovascular diseases, standard prophylactic CHF treatment should be applied at an early stage.PMID:35979233 | PMC:PMC9376878 | DOI:10.3389/fphar.2022.890546 (Source: Cancer Control)
Source: Cancer Control - August 18, 2022 Category: Cancer & Oncology Authors: Wei Pan Li Yin Yadi Guo Dachao Pan Hui Huang Source Type: research
IJERPH, Vol. 19, Pages 10156: The Impact of International Nonproprietary Names Integration on Prescribing Reimbursement Medicines for Arterial Hypertension and Analysis of Medication Errors in Latvia
rtāne
The use of international nonproprietary names (INNs) has been mandatory for prescriptions of state-reimbursed drugs in Latvia since 1 April 2020. In a retrospective analysis, we aimed to examine the impact of the new regulation on changes in the prescribing and dispensing practice of antihypertensive agents with an example of bisoprolol or/and perindopril and their combinations. All state-reimbursed bisoprolol and/or perindopril prescriptions for arterial hypertension were evaluated in two time periods: 1 April 2018 to 31 March 2019 and 1 April 2020 to 31 March 2021. The proportion of INN prescriptions increased...
Source: International Journal of Environmental Research and Public Health - August 16, 2022 Category: Environmental Health Authors: Anna Gavrilova Maksims Zolovs Gustavs Latkovskis Inga Urt āne Tags: Article Source Type: research
Can Pediatric Heart Failure Therapy Be Improved? Yes It Can, But …
AbstractGiven the heterogenous etiology of pediatric heart failure (pHF), evidence-based studies improving pHF are unlikely. A paradigm shift towards updated medicine-based evidence is therefore necessary. In view of the life expectancy of children, cardiac regeneration strategies are required. Therefore, age- and disease-related differences in myocardial (receptor) physiology require individualized precision medicine. First-line diuretic therapy, adopted from the treatment of adults with HF with no chance for recovery, should be questioned in the treatment of pHF with potential for recovery. Inadequate use of diuretics is...
Source: Pediatric Drugs - August 6, 2022 Category: Pediatrics Source Type: research
Can Pediatric Heart Failure Therapy Be Improved? Yes It Can, But …
Paediatr Drugs. 2022 Aug 6. doi: 10.1007/s40272-022-00524-z. Online ahead of print.ABSTRACTGiven the heterogenous etiology of pediatric heart failure (pHF), evidence-based studies improving pHF are unlikely. A paradigm shift towards updated medicine-based evidence is therefore necessary. In view of the life expectancy of children, cardiac regeneration strategies are required. Therefore, age- and disease-related differences in myocardial (receptor) physiology require individualized precision medicine. First-line diuretic therapy, adopted from the treatment of adults with HF with no chance for recovery, should be questioned ...
Source: Paediatric Drugs - August 5, 2022 Category: Pediatrics Authors: Dietmar Schranz Source Type: research
Can Pediatric Heart Failure Therapy Be Improved? Yes It Can, But …
Paediatr Drugs. 2022 Aug 6. doi: 10.1007/s40272-022-00524-z. Online ahead of print.ABSTRACTGiven the heterogenous etiology of pediatric heart failure (pHF), evidence-based studies improving pHF are unlikely. A paradigm shift towards updated medicine-based evidence is therefore necessary. In view of the life expectancy of children, cardiac regeneration strategies are required. Therefore, age- and disease-related differences in myocardial (receptor) physiology require individualized precision medicine. First-line diuretic therapy, adopted from the treatment of adults with HF with no chance for recovery, should be questioned ...
Source: Paediatric Drugs - August 5, 2022 Category: Pediatrics Authors: Dietmar Schranz Source Type: research
Can Pediatric Heart Failure Therapy Be Improved? Yes It Can, But …
Paediatr Drugs. 2022 Aug 6. doi: 10.1007/s40272-022-00524-z. Online ahead of print.ABSTRACTGiven the heterogenous etiology of pediatric heart failure (pHF), evidence-based studies improving pHF are unlikely. A paradigm shift towards updated medicine-based evidence is therefore necessary. In view of the life expectancy of children, cardiac regeneration strategies are required. Therefore, age- and disease-related differences in myocardial (receptor) physiology require individualized precision medicine. First-line diuretic therapy, adopted from the treatment of adults with HF with no chance for recovery, should be questioned ...
Source: Paediatric Drugs - August 5, 2022 Category: Pediatrics Authors: Dietmar Schranz Source Type: research
